Abstract: The present invention relates to a composition for bone regeneration comprising METTL7A-overexpressing stem cells, a method for preparing the same, and a cell therapy product comprising the same. According to the invention, it is possible to enhance the osteogenic differentiation ability and viability of stem cells compared to conventional stem cell therapy products for bone regeneration.

Abstract: The present invention relates to a non-viral minicircle vector expressing a SOX gene, a stem cell into which the vector is introduced, a pharmaceutical composition for preventing or treating a cartilage disease, including the stem cell, and a method for constructing the vector. The transformation of mesenchymal stem cells with MC/SOX-Trio or MC/SOX-Duo, which is a non-viral minicircle vector according to the present invention, can completely exclude the necessity of expensive growth factors that have been indispensably used in inducing the differentiation of mesenchymal stem cells into chondrocytes. Accordingly, the mesenchymal stem cells transformed therewith, when implanted in vivo, can differentiate into chondrocytes by themselves, and thus have an advantage capable of simplifying the existing complicated steps of culturing cells to induce differentiation and then transplanting the cells.

Abstract: The present invention relates to a polymeric micelle including a kartogenin derivative, a hyaluronic acid hydrogel including the same, a method for producing the same, and a use thereof, and the polymeric micelle and the hyaluronic acid derivative hydrogel including the polymeric micelle slowly release kartogenin, and thus may be usefully used for the purpose of preventing or treating various cartilage disorder-related diseases such as degenerative arthritis because an effect of regenerating chondrocytes while protecting chondrocytes is excellent.

Abstract: The present invention relates to a non-viral minicircle vector expressing a SOX gene, a stem cell into which the vector is introduced, a pharmaceutical composition for preventing or treating a cartilage disease, including the stem cell, and a method for constructing the vector. The transformation of mesenchymal stem cells with MC/SOX-Trio or MC/SOX-Duo, which is a non-viral minicircle vector according to the present invention, can completely exclude the necessity of expensive growth factors that have been indispensably used in inducing the differentiation of mesenchymal stem cells into chondrocytes. Accordingly, the mesenchymal stem cells transformed therewith, when implanted in vivo, can differentiate into chondrocytes by themselves, and thus have an advantage capable of simplifying the existing complicated steps of culturing cells to induce differentiation and then transplanting the cells.

Abstract: The present invention relates to kartogenin-conjugated chitosan particles with an improved sustained release property and biocompatibility. Effects of increases in biocompatibility, chondrogenic differentiation efficiency and retention time in the joints were confirmed by using kartogenin-chitosan microparticles or kartogenin-chitosan nanoparticles of the present invention, and thus targeted treatment, in the prevention or treatment of bone diseases, is enabled through a more fundamental approach.

Abstract: The present invention relates to a Krueppel-like factor 10 (KLF10) gene expression inhibitor promoting cartilage differentiation, and more specifically, to: a composition for promoting chondrocyte differentiation or treating cartilage diseases, containing a KLF10 gene expression inhibitor promoting cartilage differentiation and inhibiting the hypertrophy and dedifferentiation of chondrocytes; a cell therapeutic agent containing the composition; a method for promoting cartilage differentiation in bone marrow stem cells, comprising a step of expressing the composition in bone marrow stem cells; and a method for screening a chondrocyte differentiation promoter or a chondrocyte therapeutic agent.

Abstract: The present invention relates to kartogenin-conjugated chitosan particles with an improved sustained release property and biocompatibility. Effects of increases in biocompatibility, chondrogenic differentiation efficiency and retention time in the joints were confirmed by using kartogenin-chitosan microparticles or kartogenin-chitosan nanoparticles of the present invention, and thus targeted treatment, in the prevention or treatment of bone diseases, is enabled through a more fundamental approach.

Abstract: The present invention relates to a Krueppel-like factor 10 (KLF10) gene expression inhibitor promoting cartilage differentiation, and more specifically, to: a composition for promoting chondrocyte differentiation or treating cartilage diseases, containing a KLF10 gene expression inhibitor promoting cartilage differentiation and inhibiting the hypertrophy and dedifferentiation of chondrocytes; a cell therapeutic agent containing the composition; a method for promoting cartilage differentiation in bone marrow stem cells, comprising a step of expressing the composition in bone marrow stem cells; and a method for screening a chondrocyte differentiation promoter or a chondrocyte therapeutic agent.